文献速递血栓与止血

重组凝血因子VIII Fc融合蛋白用于首次免疫耐受诱导:verITI-8研究最终结果

Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study.
PubMed 文献 · Blood · 2023-01-01

verITI-8是首个评估重组凝血因子VIII Fc融合蛋白(rFVIIIFc)用于重型血友病A伴高滴度抑制物男性患者首次免疫耐受诱导(ITI)的前瞻性研究。单臂、开放标签、多中心设计,rFVIIIFc 200 IU/kg每日给药至耐受或最长48周。16例患者中约三分之二在48周内达到耐受,耐受时间短且耐受性良好。

要点

  • 16例中12例(75%)在48周内抑制物滴度转阴,11例(69%)达到IR≥66%,10例(63%)达到t½≥7小时。
  • 达到抑制物转阴、IR≥66%、t½≥7小时的中位时间分别为7.4、6.8、11.7周。
  • 所有患者发生至少1例治疗中出现的不良事件,9例发生至少1例治疗中出现的严重不良事件,无血栓事件、因不良事件停药或死亡。

核心结论

  • 作为首个在ITI中拥有前瞻性数据的延长半衰期rFVIII,rFVIIIFc使近三分之二患者实现短时间耐受且应答持久,耐受性良好。

研究设计与样本

  • verITI-8为单臂、开放标签、多中心前瞻性研究,纳入重型血友病A伴高滴度抑制物(历史峰值≥5 Bethesda单位[BU]/mL)的男性患者。
  • 筛查后进入ITI阶段,rFVIIIFc 200 IU/kg每日给药,直至耐受或最长48周。
  • 达到ITI成功者进入减量期,恢复标准预防治疗,随后进入随访期。
  • 16例患者接受至少1剂rFVIIIFc。
  • 试验注册号为NCT03093480。

主要发现

  • 12例(75%)在48周内达到抑制物滴度<0.6 BU/mL,11例(69%)达到IR≥66%预期IR(IR≥1.32 IU/dL per IU/kg),10例(63%)达到t½≥7小时即耐受。
  • 达到抑制物转阴、IR≥66%、t½≥7小时的中位时间分别为7.4周(IQR 2.2-17.8)、6.8周(IQR 5.4-22.4)、11.7周(IQR 9.8-26.2)。
  • 所有患者发生至少1例治疗中出现的不良事件(TEAE),1例报告至少1例相关TEAE(注射部位疼痛)。
  • 9例患者发生至少1例治疗中出现的严重不良事件。
  • 研究期间未报告血栓事件、因不良事件停药或死亡。

关键数值与推荐

  • ITI成功(耐受)定义:48周内抑制物滴度<0.6 BU/mL、IR≥66%预期IR(IR≥1.32 IU/dL per IU/kg)且t½≥7小时。
  • rFVIIIFc给药方案:200 IU/kg每日,直至耐受或最长48周。
  • 高滴度抑制物定义:历史峰值≥5 BU/mL。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Inhibitor development remains a major challenge in factor VIII (FVIII) replacement therapy. verITI-8 is the first prospective study of a recombinant FVIII Fc fusion protein (rFVIIIFc; efmoroctocog alfa) for first-time immune tolerance induction (ITI) in males with severe hemophilia A and high-titer inhibitors (historical peak ≥5 Bethesda units [BU]/mL). In this single-arm, open-label, multicenter study, screening was followed by ITI (rFVIIIFc 200 IU/kg per day until tolerization or maximum of 48 weeks). Those who achieved ITI success entered a tapering period, returning to standard prophylaxis, and then entered follow-up. Primary end point was time to tolerization with rFVIIIFc defined by inhibitor titer <0.6 BU/mL, incremental recovery (IR) ≥66% of expected IR (IR ≥1.32 IU/dL per IU/kg), and half-life (t½) ≥7 hours within 48 weeks. Sixteen patients received ≥1 rFVIIIFc dose. Twelve (75%), 11 (69%), and 10 patients (63%), respectively, achieved negative inhibitor titers, an IR ≥66%, and a t½ ≥7 hours (ie, tolerance) within 48 weeks. Median times in weeks to achieve these markers of success were 7.4 (interquartile range [IQR], 2.2-17.8), 6.8 (IQR, 5.4-22.4), and 11.7 (IQR, 9.8-26.2), respectively. All patients experienced ≥1 treatment-emergent adverse event (TEAE), and 1 reported ≥1 related TEAE (injection site pain). Nine patients experienced ≥1 treatment-emergent serious AE. No thrombotic events, discontinuations because of AEs, or deaths were reported during the study. As the first extended half-life rFVIII with prospective data in ITI, rFVIIIFc offered short time to tolerization with durable responses in almost two-thirds of patients and was well tolerated. This trial was registered at www.clinicaltrials.gov as #NCT03093480.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Malec L, Van Damme A, Chan AKC, et al. Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study. Blood. 2023. PMID: 36735911. doi:10.1182/blood.2022017780

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。